Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach